Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Brainomix
Stroke and lung imaging AI
Diagnostics & imaging
Oxford University spinout building AI imaging biomarkers for stroke and lung disease, used to speed emergency treatment decisions from CT and MRI scans.
The read
Brainomix 360 is an AI imaging platform originally built to speed stroke triage by automating scoring of CT brain scans, since extended into lung fibrosis and lung cancer imaging. The software flags markers such as ischaemic core volume directly to clinicians, cutting the time between a scan and a treatment decision such as thrombectomy.
A Lancet Digital Health study of over 450,000 patients across 107 NHS England hospitals found its use associated with increased thrombectomy rates. In 2026 it rolled out across all 25 sites of West Virginia University Health System, extending its NHS-built evidence base into the US market.
The Bridgehead view
Brainomix's growth is a useful proof point for how far regulatory-first, NHS-embedded AI diagnostics can travel once peer-reviewed, multi-year clinical evidence exists to de-risk procurement for other health systems.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
Related platforms
Others in the sector map
Lung cancer diagnosis AI
Optellum
AI decision-support software that stratifies the cancer risk of lung nodules found on CT scans, the first such tool cleared by the FDA.
ReadDermatology AI
Skin Analytics
AI-powered skin cancer detection device, DERM, deployed directly within NHS urgent skin cancer pathways to autonomously rule out low-risk cases.
ReadThe firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
